Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 2/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112232 | 0.92 | RXFP1 (0.43) | RAB9AMAPK14HSD11B1TTKMAPK11 | |
| SCHEMBL3105220 | 0.90 | RAB9A (0.46) | RAB9AHSD11B1TTKRXFP1ROCK1 | |
| SCHEMBL13158446 | 0.87 | PTGS2 (0.46) | RAB9AALDH1A1MAPK14HTTMAPK11 | |
| SCHEMBL3109046 | 0.87 | KMT2A (0.51) | RAB9AALDH1A1HSD11B1RXFP1MAPT | |
| SCHEMBL3114886 | 0.87 | RAB9A (0.41) | RAB9AALDH1A1MAPK14HSD11B1RXFP1 | |
| SCHEMBL3110448 | 0.87 | PLK1 (0.42) | RAB9AHSD11B1TTKRXFP1ROCK1 | |
| SCHEMBL3110326 | 0.87 | ALDH1A1 (0.48) | RAB9AALDH1A1HTTROCK1NAMPT | |
| SCHEMBL3110919 | 0.86 | MAPK14 (0.45) | MAPK14HSD11B1TTKMAPK11RXFP1 | |
| SCHEMBL3107213 | 0.86 | CHRNA10 (0.42) | RAB9AMAPK14HSD11B1TTKMAPK11 | |
| SCHEMBL3117669 | 0.86 | HSD11B1 (0.46) | RAB9AMAPK14HSD11B1MAPK11ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | RAB9A 2959/4885ALDH1A1 3580/4885MAPK14 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.